Strength Training While on GLP-1 Medications: The Science-Backed Guide to Preserving Muscle

Here is a number that should stop every man on semaglutide or tirzepatide in his tracks: during the landmark 68- to 72-week clinical trials, participants lost roughly 10% or more of their total muscle mass — a figure that researchers from a 2025 review in Obesity Reviews describe as approximately equivalent to 20 years of age-related muscle loss. Not two years. Twenty. The medications are working exactly as intended — suppressing appetite, reducing caloric intake, and driving the scale downward — but without deliberate intervention, a substantial portion of what you are losing is not fat. It is the metabolically active, functionally critical tissue that determines how you move, how your body processes glucose, and how quickly you age.

This is not a reason to avoid GLP-1 medications. The cardiovascular, metabolic, and weight-loss benefits documented across multiple large trials are real and meaningful. But the science is now unambiguous on one point: if you are on a GLP-1 receptor agonist — liraglutide, semaglutide, tirzepatide, or any of the newer incretin-based therapies — and you are not resistance training, you are leaving the most important part of the protocol on the table. Strength training is not optional for GLP-1 users. It is the single most effective tool available to ensure the weight you lose is fat, not muscle.

Why GLP-1 Medications Create a Muscle Loss Problem

To understand why resistance training becomes so critical in this context, it helps to understand what GLP-1 receptor agonists are actually doing to your body. These medications work primarily by mimicking the glucagon-like peptide-1 hormone, which slows gastric emptying, reduces appetite, and improves insulin signaling. The result is a significant and sustained caloric deficit — often without the hunger that makes traditional dieting so psychologically grueling. That deficit is powerful. A 2024 narrative review in Diabetes Care found that liraglutide, semaglutide, tirzepatide, and the newer triple-agonist retatrutide induce between 15% and 24% total body weight loss, with meaningful improvements in blood pressure, cholesterol, blood glucose, and insulin sensitivity alongside it.

But that same review quantified what has become one of the most pressing concerns in obesity medicine: these agents also cause rapid and significant loss of lean mass — approximately 10%, or roughly 6 kilograms, comparable to more than a decade of aging. The mechanism is straightforward and applies to any aggressive caloric deficit, with or without medication. When the body is in a sustained energy shortfall, it does not exclusively burn stored fat. It also breaks down muscle tissue for energy and amino acids, particularly when protein intake is inadequate and the muscles are not receiving a consistent training signal that signals their preservation is a physiological priority.

A separate 2025 review published in Current Opinion in Clinical Nutrition and Metabolic Care reinforced just how substantial this issue is, noting that up to 40% of total weight loss during GLP-1 receptor agonist therapy can come from fat-free mass — the category that includes skeletal muscle. Fat-free mass loss of that magnitude is not a cosmetic concern. Skeletal muscle is the largest site of glucose disposal in the body. Losing it accelerates insulin resistance, reduces resting metabolic rate, increases the risk of sarcopenia, and dramatically raises the probability of rapid weight regain if the medication is discontinued. The downstream consequences of ignoring muscle preservation during GLP-1 therapy are, in the long run, metabolically counterproductive to the very goals the medication is meant to serve.

A major 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society was explicit on this point. The panel identified resistance training and appropriate dietary strategies as essential components of GLP-1 therapy, recommending that clinicians assess muscle strength, function, and body composition as part of every patient’s baseline evaluation. The advisory also highlighted that low long-term adherence to GLP-1 medications, followed by weight regain, represents one of the drug’s most significant real-world limitations — and that maintaining lean mass through exercise and nutrition is one of the strongest buffers against that rebound.

What the Research Says About Resistance Training as a Countermeasure

The evidence for resistance training as the primary intervention to offset GLP-1-induced muscle loss is well-established, and it is more encouraging than most men might expect. The 2024 Diabetes Care review found that supervised resistance exercise programs lasting more than 10 weeks produced average lean mass gains of approximately 3 kilograms and strength improvements of around 25% in men and women with overweight and obesity. To put that in context: while GLP-1 medications are removing roughly 6 kilograms of lean mass over a 68-week trial, consistent resistance training has the documented capacity to restore 3 or more kilograms of that loss and simultaneously increase functional strength by a quarter. The gap between those two trajectories — one with training, one without — is the difference between a transformation and a metabolic setback.

The 2025 Obesity Reviews paper by Mechanick, Butsch, Christensen and colleagues drew a clear and actionable conclusion from this body of evidence: all patients receiving incretin-mimetic drugs for obesity should participate in comprehensive treatment programs emphasizing resistance training to preserve muscle mass and function, maximize the benefit of drug therapy, and minimize potential risks. That is not a qualified recommendation. It is a blanket one, grounded in the recognition that no pharmaceutical or nutritional strategy currently available matches the muscle-preserving signal generated by progressive mechanical loading.

There is also a compelling case being made for resistance training as a way to protect the long-term durability of GLP-1 results. One of the most significant limitations of these medications is what happens when patients stop taking them — typically due to cost, side effects, or medication access issues. Weight regain is common and often rapid. However, retaining lean mass during the weight loss phase meaningfully raises resting metabolic rate and improves body composition, creating a physiological environment that is more resistant to fat regain. The Diabetes Care review makes this point directly, proposing that retaining lean mass during incretin therapy could blunt both body weight and fat regain on cessation of pharmacotherapy. In other words, the hours you put into the weight room while on GLP-1 medication are not just protecting your muscles today — they are protecting your results for years after the medication stops.

The 2025 review on sarcopenic obesity published in Current Opinion in Clinical Nutrition and Metabolic Care added further nuance by noting that structured exercise interventions, especially resistance training, play a key role in mitigating fat-free mass loss during incretin-based weight loss pharmacotherapy, and that digital health and telemedicine-based exercise programs offer promising scalable approaches for men who cannot access in-person supervision. The practical implication is clear: format matters less than consistency. Whether you are training in a commercial gym, a home setup, or following a remote coaching program, the muscle-preserving signal from progressive resistance exercise is largely the same — and it needs to be present throughout the entire duration of GLP-1 therapy.

How to Structure Your Training and Nutrition While on GLP-1s

Understanding the problem is one thing. Building a practical program around it is another. The good news is that the research does not demand elite-level training to produce meaningful results. What it demands is consistency, progressive overload, and sufficient protein to support the anabolic signaling that resistance training triggers.

For most men on GLP-1 medications, three to four resistance training sessions per week targeting all major muscle groups is both achievable and well-supported by the literature. Compound movements — squats, Romanian deadlifts, rows, pressing patterns, and hip hinges — should form the foundation because they recruit the largest volume of muscle tissue per session, generating the strongest systemic hormonal and mechanical response. Isolation work can supplement these movements but should not replace them. Training intensity matters: working in the range of 6 to 15 repetitions per set, taken to within two to three reps of muscular failure, consistently outperforms lower-effort approaches in lean mass preservation studies. Progressive overload — adding weight, reps, or sets over time — is the mechanism that tells your body to hold onto muscle even as the scale is dropping.

Protein intake is the nutritional complement that makes resistance training work in this context, and the two strategies must be paired deliberately. The appetite suppression induced by GLP-1 medications is powerful and often indiscriminate — men frequently find themselves eating far less without necessarily prioritizing the macronutrient that matters most for muscle retention. The 2025 joint advisory from the four major medical societies identified preventing nutrient deficiencies and preserving muscle mass through both resistance training and appropriate diet as two of the most critical priorities during GLP-1 use. High-quality protein — from sources like lean meats, eggs, Greek yogurt, cottage cheese, fish, and quality protein supplements when whole food intake is low — should be consumed at a minimum of 1.6 grams per kilogram of body weight daily, with emerging evidence suggesting that men in a significant caloric deficit may benefit from pushing closer to 2.0 to 2.4 grams per kilogram to adequately stimulate muscle protein synthesis.

Distributing protein across three to four meals throughout the day, rather than concentrating it in one or two large servings, appears to optimize the muscle protein synthesis response. Given that GLP-1 medications often reduce portion tolerance and meal frequency spontaneously, men may need to make deliberate, structured choices about when and how they eat protein — rather than relying on hunger cues that the medication is actively suppressing.

Several specific nutrients have also shown promise as adjuncts to resistance training and protein intake in this context. The 2025 Current Opinion review on GLP-1 nutrition support highlighted branched-chain amino acids, creatine, leucine, omega-3 fatty acids, and vitamin D as potentially beneficial nutrients for preserving muscle mass when dietary intake alone is insufficient. Among these, creatine monohydrate has the most robust evidence base across decades of research — it supports strength output, lean mass retention, and cellular energy availability, and is one of the few supplements with a genuine mechanistic rationale for use during a GLP-1-induced caloric deficit. Vitamin D insufficiency, which is common in men with obesity, has been linked to impaired muscle function and should be assessed and corrected as part of any GLP-1 management program. Omega-3 fatty acids from fish oil have shown anti-inflammatory and anti-catabolic properties in several resistance training studies, making them a reasonable addition to the stack.

Beyond the mechanics of training and nutrition, sleep and stress management deserve mention because they are underappreciated regulators of muscle retention. Cortisol, the primary stress hormone, is catabolic — it accelerates muscle protein breakdown, particularly during periods of caloric restriction. Men who are sleeping fewer than seven hours per night or managing high chronic stress are compounding the muscle loss risk that GLP-1 medications already create. The joint advisory from the four medical societies explicitly included sleep and mental stress as lifestyle factors that clinicians should assess at baseline and address throughout treatment. These are not peripheral concerns. They are central levers in the body composition equation.

The Takeaway

GLP-1 medications represent a genuine advance in obesity medicine, and for many men they are a legitimate and effective tool for driving meaningful, sustained weight loss. But the clinical data makes one thing unmistakably clear: the medications alone do not optimize body composition. They reduce total body weight, and without a deliberate resistance training protocol and adequate protein intake, a substantial portion of that reduction comes at the expense of muscle — the very tissue that determines metabolic rate, insulin sensitivity, physical function, and long-term weight maintenance. The research does not position strength training as a nice-to-have adjunct to GLP-1 therapy. It positions it as a clinical imperative, supported by a 2025 joint advisory from four major medical organizations and multiple systematic reviews drawing the same conclusion from independent analyses. If you are on a GLP-1 medication and not lifting weights consistently, you are not running a complete program. Start the resistance training. Prioritize your protein. The medication is doing its part — now do yours.